Compare MRNA & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | BIO |
|---|---|---|
| Founded | 2010 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.2B |
| IPO Year | 2018 | N/A |
| Metric | MRNA | BIO |
|---|---|---|
| Price | $25.14 | $319.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | $33.91 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 10.0M | 156.6K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,232,000,000.00 | ★ $2,557,500,000.00 |
| Revenue This Year | N/A | $1.89 |
| Revenue Next Year | $0.77 | $2.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.28 | $211.43 |
| 52 Week High | $48.92 | $373.69 |
| Indicator | MRNA | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 52.57 |
| Support Level | $23.92 | $298.35 |
| Resistance Level | $26.00 | $328.07 |
| Average True Range (ATR) | 1.19 | 10.38 |
| MACD | 0.09 | 0.29 |
| Stochastic Oscillator | 72.59 | 60.79 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.